E Bu Shi Cao (Centipeda Herb)

Chinese Herb Actions

Chinese Herb Dosage

• What is the typical dosage of E Bu Shi Cao?

  About 3–9 g per day decocted internally is the standard range given across materia medica sources (some give 6–9 g). For external use on sores or insect/snake bites, an appropriate amount of the fresh herb is pounded into a paste and applied topically; for nasal congestion the fresh juice or a dried-powder preparation has traditionally been used as nose drops or a light insufflation, in small amount, since it is a strong local irritant that reliably provokes sneezing.

  Source: materia medica consensus (Bensky 3rd ed.; multiple published TCM herb references). Reference only — not a prescription.

Chinese Herb Contraindications & Cautions

• Are there cautions for E Bu Shi Cao?

  E Bu Shi Cao is acrid, warm, and locally irritating, so it is traditionally avoided in wind-heat patterns (its warming, dispersing action can aggravate heat signs), and care is taken to keep fresh preparations away from the eyes and broken or sensitive skin, since the fresh juice is a classic nasal irritant that reliably provokes sneezing. Internal use should stay within standard dosage, and those with a sensitive stomach or a history of peptic ulcer/gastritis are traditionally advised to take it after food and avoid overdosing.

  • Wind-heat patterns — generally avoided; the warm, acrid dispersing action does not suit heat presentations.
  • Eyes and broken skin — keep fresh preparations away from the eyes; local irritation (stinging, sneezing) is expected with nasal use and is part of its traditional action, not a sign of misuse at normal doses.
  • Digestive sensitivity — caution with weak digestion, gastritis, or peptic ulcer history; take with food.

  Note: Some classical references list E Bu Shi Cao for eye conditions (nebula, pterygium), while modern sources uniformly warn to keep the irritant fresh juice away from the eyes. These likely reflect different, more dilute historical eye preparations rather than a contradiction, but we flag it since we could not verify the classical eye-application method in detail.

  Source: materia medica consensus; cross-checked against multiple published TCM herb references. Pregnancy/lactation safety data is insufficient to state a position here — use only under a qualified practitioner.

Chinese Herb Toxicity & Overdose

• Low, with good tolerability reported in the research literature. A 2024 phytochemistry/pharmacology/safety review found no significant hepatotoxicity or nephrotoxicity in animal studies, and reported that the herb generally poses no notable irritation to major organs at studied doses. Clinical adverse reactions, where documented, are transient and mild — most commonly gastrointestinal (burning sensation, nausea, abdominal discomfort) with internal use, or local irritation (stinging, sneezing) with nasal/topical use; the same review noted transient adverse reactions in roughly one-fifth of allergic-rhinitis patients across the trials it summarized.

  Source: PMID 38202691, PMC 10779596, DOI 10.3390/molecules29010108 (2024 review of phytochemistry, pharmacology, and safety). Reference note, not a safety guarantee.

Herb-Drug Interactions

• No well-established clinical herb–drug interactions are documented for E Bu Shi Cao. Because of its local irritant potential, avoid combining fresh or concentrated preparations with other nasal irritants or decongestant treatments without practitioner guidance; this is precautionary, not a demonstrated interaction. (Flagged for practitioner confirmation.)

Western / Biomedical Research

Chinese Herb Clinical Studies & Research

Provided as research context — a summary of published biomedical study, not a therapeutic or medical claim.

• Is there modern research on E Bu Shi Cao (Centipeda minima)?

  Yes — a growing body of phytochemical and preclinical research, with the strongest translational interest around allergic rhinitis and inflammation. Sesquiterpene lactones (notably brevilin A) along with flavonoids and volatile oils are established as key bioactive constituents.

  • Allergic rhinitis (animal model) — in an ovalbumin-induced rat model of allergic rhinitis, nasal administration of Centipeda minima volatile oil reduced nasal mucosal damage and glandular hyperplasia and lowered inflammatory markers (TNF-α, IL-4, IgE) versus controls, supporting the traditional nose-opening/anti-congestion use.
  • Fresh vs. dried herb, immune modulation — a 2025 study found fresh Centipeda minima predominantly suppressed Th2 allergic signaling (lower IgE, IL-6; higher IL-10), while dried material instead enhanced Th1 activity, identifying neocnidilide and 6-gingerol as key bioactive compounds — a reminder that fresh vs. dried processing may matter for its nasal/allergic actions.
  • Anti-inflammatory mechanism (brevilin A) — brevilin A, isolated from the herb, protected mice from LPS-induced acute lung injury by covalently binding IKKα/β and blocking NF-κB activation, reducing pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) — a plausible mechanism supporting traditional cough/wheeze and anti-inflammatory uses. Preclinical (mouse/cell) evidence.
  • Skin/topical relevance — Centipeda minima extract and brevilin A reduced TNF-α-induced oxidative stress and collagen breakdown in human dermal fibroblasts in vitro, offering laboratory-level support for its traditional topical use on sores and inflamed skin.
  • Broader pharmacology and safety — a 2024 review also documents anticancer activity in preclinical models (nasopharyngeal, non-small-cell lung, triple-negative breast, liver, and gastric cancer cell lines) and antimicrobial activity of the volatile oil; see Toxicity for its safety findings.

  Human clinical evidence is still limited relative to the volume of preclinical/phytochemical work; most support to date is animal or cell-based.

  Sources: PMID 34010591, PMC 8143626, DOI 10.1080/13880209.2021.1923757 (rat allergic-rhinitis model); PMID 40943597, PMC 12429449, DOI 10.3390/ijms26178678 (fresh vs. dried, Th1/Th2 modulation); PMID 35774606, DOI 10.3389/fphar.2022.911157 (brevilin A, acute lung injury, NF-κB mechanism); PMID 40699775, PMC 12110285, DOI 10.3390/cimb47050376 (dermal fibroblasts, TNF-α-induced damage); PMID 38202691, PMC 10779596, DOI 10.3390/molecules29010108 (2024 review: phytochemistry, pharmacology, anticancer/antimicrobial findings, safety). Research context, not a therapeutic claim.

Chinese Herb Notes

• What herbs is E Bu Shi Cao combined with for nasal congestion and sinusitis?

  E Bu Shi Cao is most often paired with other nose-opening herbs — especially Xin Yi Hua and Cang Er Zi — for chronic nasal congestion, rhinitis, and sinusitis, and with Bai Zhi and Xi Xin when wind-cold headache accompanies the stuffy nose.

  • Xin Yi Hua + Cang Er Zi — the classic nasal-opening pair; Xin Yi Hua aromatically opens the more superficial passages while Cang Er Zi dredges deeper congestion. E Bu Shi Cao is added alongside them, and is noted in practice for its distinct sneeze-inducing, locally irritant clearing action.
  • Bai Zhi, Xi Xin — combined for wind-cold headache with a blocked or runny nose.
  • Patent-formula context — E Bu Shi Cao appears alongside Cang Er Zi, Xin Yi Hua, Fang Feng, Bo He, and other exterior-releasing/toxin-resolving herbs in nasal-congestion patent formulas (e.g. Bi Min Gan Wan–type products) aimed at rhinitis-type presentations. (Formula context for reference, not treatment advice.)

  Source: materia medica consensus; published TCM herb references on nasal-opening combinations.